No abstract available.
Brassica* ; Ear*

Morphological characteristics of human embryos of Carnegie stage 17 were described. The crown rump length of these embryos were 11.7-13.6mm. These embryos were characterized externally by ventrally directed nasal pits, 6 distinct auricular hillocks, finger rays in the hand plate, digital plate at the lower limb bud, herniation of a part of midgut through umbilical cord, and internally by the partial fusion of ventral and dorsal pancreas, prominent nasal sac which is not open to primitive oral cavity, formation of segmental and some subsegmental bronchial buds, branching of metanephrotic pelvis, crescent-shaped lens cavity, and imminent semicircular ducts.
Crown-Rump Length ; Embryonic Structures* ; Fingers ; Hand ; Humans* ; Lower Extremity ; Mouth ; Pancreas ; Pelvis ; Semicircular Ducts ; Umbilical Cord

OBJECTIVE: The aims of this study were to analyze the natural history of patients with pseudomyxoma peritonei originated from mucinous ovarian tumor, evaluate clinical and pathologic variables, and review our experience with available therapeutic modalities. METHODS: Six patients were treated for pseudomyxoma peritonei originating from mucinous ovarian tumor at Severance Hospital between 1990 and 1998. The data were collected retrospectively and all charts were reviewed RESULTS: The mean age at diagnosis was 51 years, and most common symptoms were abdominal distension. Pseudomyxoma peritonei was found in association with five mucinous ovarian tumors of borderline malignancy, and one ovarian mucinous adenoma. All patients underwent surgical staging and cytoreduction, three patients received postoperative adjuvant chemotherapy and, of these, two developed recurrence. With respect to survival, all patients were alive, four were alive and free of disease, two were alive with disease at the end point of study. CONCLUSION: Pseudomyxoma peritonei is commonly associated with borderline mucinous ovarian tumors, and is a frequently relapsing and protracted disease. But aggressive and repeated debulking surgery is recommended for long survival.
Adenoma ; Chemotherapy, Adjuvant ; Diagnosis ; Humans ; Mucins* ; Natural History ; Pseudomyxoma Peritonei* ; Recurrence ; Retrospective Studies

No abstract available.
Nasal Bone*

BACKGROUND: Fluid overload prior to continuous renal replacement therapy (CRRT) is an important prognostic factor. Thus, precise evaluation of fluid status is necessary to treat such patients. In this study, we investigated whether fluid assessment using bioelectrical impedance analysis (BIA) can predict outcomes in critically ill patients requiring CRRT. METHODS: A prospective observational study was performed in patients who were admitted to the intensive care unit and who required CRRT. BIA was conducted before CRRT; then, the ratio of extracellular water to total body water (ECW/TBW) was derived to estimate volume status. RESULTS: A total of 31 patients treated with CRRT were included. There were 18 men (58.1%), and the median age was 67 years (interquartile range, 51 to 78 years). Fourteen patients (45.2%) died within 28 days after CRRT initiation. Patients were divided into 16 with ECW/TBW ≥0.41 and 15 with ECW/TBW <0.41. Survival rate within 28 days was different between the two groups (P = 0.044). Cox regression analysis revealed a relationship between ECW/TBW ≥0.41 and 28-day mortality, but it was not statistically significant (hazard ratio, 3.0; 95% confidence interval, 0.9 to 9.8; P = 0.061). Lastly, the area under the curve of ECW/TBW for 28-day mortality was analyzed. The area under the curve of ECW/TBW was 0.73 (95% confidence interval, 0.54 to 0.92), and this was significant (P = 0.037). CONCLUSIONS: Fluid status can be assessed using BIA in critically ill patients requiring CRRT, and BIA can predict mortality. Further large trials are needed to confirm the usefulness of BIA in critically ill patients.
Body Water ; Critical Illness* ; Electric Impedance* ; Humans ; Intensive Care Units ; Male ; Mortality ; Observational Study* ; Prospective Studies* ; Renal Replacement Therapy* ; Survival Rate ; Water

No abstract available.
Extracorporeal Circulation* ; Pulmonary Atresia* ; Ventricular Septum*

No abstract available.
Calcium* ; Lithium* ; Parathyroid Hormone*

No abstract available.
Adult* ; Anatomic Landmarks* ; Humans ; Vertical Dimension*

This study was performed to evaluate the clinical significance of SCC as a tumor marker in patient with squamous cell carcinoma of the cervix. We measured the serum levels of SCC by radioimmunoassay in patient with invasive squamous cell carcinoma of cervix to determine the prognostic value, correlation with the presence of lymph node metastasis, response to treatment, and those value in the early detection of recurrence after treatment. The result was: 1) In 117 of 174 patients with cervical cancer, the pretreatment positive rate of SCC was 47.0%(57/117). In each stage, the stage Ia was 25.0%, Ib 26.3%, IIa 56.0%, 62.6%, III 57.1%, IV 100%, and the recurrent case was 37.5%. 2) In 79 of 174 patients with cervical cancer, the pretreatment positive rate of SCC was 44,0%(30/69) in no evidence of malignancy patients, but 60.0%(6/10) in recurrent or permanent patients(p>0.05), 3) In 133 of 174 patients with cervical cancer, the posttreatment positive rate of SCC was 2.6%(3/117) in no evidence of malignancy patients, but 50.0%(8/16) in recurrent or permanent patients(p<0.05). 4) In 48 patients of 174 with cervical cancer who underwent radical hystrectomy, the positive rate of SCC was 71.4%(5/7) in pelvic lymph node positive patients but 19,5%(8/41) in pelvic lymph node negative patients(p<0.05). We concluded that the pretreatment SCC level was not effective as a prognostic value, but well correlated with pelvic lymph node metastasis, and serial measurements of serum levels of SCC provided a reliable clue for early detection of recurrence or progression of disease, so it may be useful for monitoring cervical carcinoma patient.
Carcinoma, Squamous Cell* ; Cervix Uteri* ; Female ; Humans ; Lymph Nodes ; Neoplasm Metastasis ; Radioimmunoassay ; Recurrence ; Uterine Cervical Neoplasms

No abstract available.
Diazepam* ; Humans ; Hypnotics and Sedatives* ; Midazolam* ; Surgery, Plastic*